Sanmina Corp.

Sanmina Corp. has achieved a new 52-week high, reflecting a substantial increase in its stock value over the past year, significantly outperforming the S&P 500. With a market cap of USD 12,249 million, the company exhibits strong financial metrics, including a low debt-to-equity ratio and a solid return on equity.

Sanmina Corp. achieved a new 52-week high of USD 196.00, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector with a one-year growth of 183.51%. The company has a market capitalization of USD 12,249 million, a P/E ratio of 39.00, and a low debt-to-equity ratio of 0.31.

Sanmina Corp. has achieved a new 52-week high, reflecting a substantial increase in its stock performance over the past year. The company, with a market capitalization of USD 12,249 million, showcases strong financial metrics, including a low debt-to-equity ratio and a solid return on equity.

Sanmina Corp., a small-cap in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation metrics, showing a P/E ratio of 39 and a price-to-book value of 4.95. The company has delivered impressive returns over one, three, and five years, outperforming the S&P 500 and highlighting its competitive position in the market.

Sanmina Corp., a small-cap in the Pharmaceuticals & Biotechnology sector, has seen notable stock performance, with significant gains over various timeframes. The company exhibits strong management efficiency, highlighted by a solid return on equity and low debt levels, alongside high institutional investor confidence.

Sanmina Corp., a small-cap in the Pharmaceuticals & Biotechnology sector, has shown strong performance with a notable one-day gain and impressive monthly growth. The company boasts solid financial metrics, including a high return on equity and low debt-to-equity ratio, alongside robust institutional holdings and significant annual returns.

Sanmina Corp., a small-cap in the Pharmaceuticals & Biotechnology sector, has adjusted its valuation, with its current price at $139.55. Over the past year, it has achieved an 86.32% return, outperforming the S&P 500. Key metrics include a P/E ratio of 44 and a ROCE of 21.25%.

Sanmina Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has recently adjusted its valuation metrics, including a P/E ratio of 44 and a price-to-book value of 5.65. The company has shown impressive returns over one, three, five, and ten years, significantly outperforming the S&P 500.

Sanmina Corp. experienced a notable gain today, significantly outperforming the S&P 500. Despite a recent monthly decline, the company showcases strong financial metrics, including a high return on equity and low debt-to-equity ratio. Its annual return remains impressive compared to broader market performance, indicating resilience amid challenges.

Sanmina Corp. has recently experienced a change in its evaluation, influenced by shifts in financial metrics and market dynamics. Key indicators show mixed signals, with some suggesting bullish trends. The company has demonstrated strong management efficiency and impressive operating cash flow, contributing to a stable financial outlook.

Sanmina Corp. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector with a significant increase over the past year. The company boasts solid financial metrics, including a favorable P/E ratio, low debt-to-equity ratio, and impressive operating cash flow, indicating robust market positioning.

Sanmina Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has shown strong performance with an 89.52% return over the past year. Despite mixed technical indicators, the company has achieved significant growth, including a 375.01% increase over the last five years, reflecting its resilience in the market.

Sanmina Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has seen a notable rise in stock performance, significantly outperforming the S&P 500 over various timeframes. The company demonstrates strong management efficiency, low debt levels, and robust financial health, supported by full institutional ownership.

Sanmina Corp., a small-cap in the Pharmaceuticals & Biotechnology sector, saw a notable stock decline on October 7, 2025. Despite this, the company has demonstrated strong performance over the past year, with significant increases in stock value, high return on equity, and solid cash flow metrics.

Sanmina Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has shown remarkable stock performance, significantly outperforming the S&P 500 over various time frames. The company boasts strong financial metrics, including a solid return on equity and record operating cash flow, with full institutional ownership indicating investor confidence.

Sanmina Corp. has achieved a new 52-week high, reflecting a significant performance increase over the past year. With a market capitalization of USD 11,620 million, the company demonstrates strong financial metrics, including a notable price-to-earnings ratio and a low debt-to-equity ratio, highlighting its solid financial foundation.

Sanmina Corp. has recently experienced a revision in its stock evaluation, reflecting its strong market position and impressive financial metrics. The company has outperformed the S&P 500 over the past year, showcasing resilience and growth. With high management efficiency and favorable debt management, Sanmina remains a notable player in the Pharmaceuticals & Biotechnology sector.